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Abstract
Background: This prospective multicenter study aimed to study the impact of the recalibration component of response-
shift (RS) on time to deterioration (TTD) in health related quality of life (QoL) scores in breast cancer (BC) patients and the
influence of baseline QoL expectations on TTD.
Methods: The EORTC-QLQ-C30 and BR-23 questionnaires were used to assess the QoL in a prospective multicenter study at
inclusion (T0), at the end of the first hospitalization (T1) and, three (T2) and 6 months after the first hospitalization (T3).
Recalibration was investigated by the then-test method. QoL expectancy was assessed at diagnosis. Deterioration was
defined as a 5-point decrease in QoL scores, considered a minimal clinically important difference (MCID). TTD was estimated
using the Kaplan-Meier method. Cox regression analyses were used to identify factors influencing TTD.
Results: From February 2006 to February 2008, 381 women were included. Recalibration of breast cancer patients’ internal
standards in the assessment of their QoL had an impact on TTD. Median TTD were significantly shorter when recalibration
was not taken into account than when recalibration was taken into account for global health, role-functioning, social-
functioning, body-image and side effects of systemic therapy. Cox multivariate analyses showed that for body image, when
recalibration was taken into account, radiotherapy was associated with a shorter TTD (HR: 0.60[0.38–0.94], whereas, no
significant impact of surgery type on TTD was observed. For global health, cognitive and social functioning dimensions,
patients expecting a deterioration in their QoL at baseline had a significantly shorter TTD.
Conclusions: Our results showed that RS and baseline QoL expectations were associated with time to deterioration in breast
cancer patients.
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Introduction
The assessment of longitudinal changes in subjective patient-
reported outcomes such as health-related quality of life (HRQoL)
is a key component of many clinical and research evaluations.
Indeed, the aim of assessing the impact of disease and treatment
on HRQoL is increasingly stressed as crucial for evaluating the
overall treatment effectiveness in cancer clinical trials. Moreover,
cancer patients require information not only related to survival
estimates, but also regarding HRQoL issues [1].
The challenge of using HRQoL measurements in longitudinal
studies or clinical trials is related to their self-report nature and also
to their subjectivity. Because measurements of HRQoL are
completed from the patient’s perspective, they could be modified
by psychological phenomena such as health expectancies [2,3].
For instance, the mechanism by which people assess or quantify
their HRQoL could change over time. These changes, which are
closely related to the process of accommodating to the illness, are
referred to as response shift (RS) [4–6]. Schwartz and Sprangers
defined response shift through three components ‘‘as a change in
the meaning of one’s self-evaluation of a target construct as a result
of a change in the respondent’s internal standards of measurement
(recalibration), a change in the respondent’s values (reprioritiza-
tion) or a redefinition of the target construct (reconceptualiza-
tion)[5]. A major goal of measuring patient-reported HRQoL is to
determine to what extent changes in HRQoL scores over time
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represent true changes in HRQoL due to treatment or cancer and
to what extent they reflect measurement error [7]. The occurrence
of RS has been demonstrated in breast cancer (BC) patients [8–
10]. Response shift is a natural process that could distort the
interpretation of change in HRQoL scores over time in
interventional comparative studies. Characterizing response shift
may therefore be a requirement to obtain a valid and sensitive
assessment of change over time.
Another concern in assessing HRQoL is how to deal with
missing data [11] since they could impact the results of HRQoL
estimates and lead to biased interpretations. Indeed, in longitu-
dinal studies, observations of patients can be missed at certain time
points because they miss visits or do not fill in some questionnaires.
In these cases, the interpretation of HRQoL results can be
seriously hampered by these missing data. Thus, analysis methods
requiring complete cases (e.g., multivariate analysis of variance)
are not adequate. Analysis methods should retain, at least, all of
the available data [11] but should produce results that are robust
and meaningful for clinicians in order to help decision making
[12,13]. In this way, the time to deterioration in QoL scores
(TTD) approach has been defined as a method of longitudinal
analysis for breast cancer (BC) patients [14]. Indeed, TTD can
deal with missing data by making underlying assumptions about
whether the missing data reflect a deterioration of the patient’s
health status or not. Furthermore, the measure of TTD might be
more familiar to clinicians because it is based on Kaplan–Meier
survival curves and hazard ratios (HR)[15].
The aims of this study were to evaluate the impact of the
recalibration component of RS on TTD estimations in patients
with BC. The secondary objective was to examine the influence of
baseline QoL expectations on TTD in patients with BC.
Methods
Patients
A prospective multicenter randomized cohort study that
included all women hospitalized for the diagnosis or treatment
of primary BC or for a suspicion of BC was implemented in the
cancer centers of Dijon, and Nancy, and in the university hospitals
of Strasbourg and Reims. Patients were included between
February 2006 and February 2008. Patients with other primary
cancer sites than BC and patients already hospitalized or treated
for BC were excluded. Only, women patients were included.
Patients who declined the study or who were unable to give a
written informed consent were excluded.
All of the participants gave their written informed consent, and
the protocol of the study was approved by the regional ethics
committee (Comite´ Consultatif de Protection des Personnes dans
la Recherche Biome´dicale de Bourgogne) in 2005.
Health related Quality of life assessments
HRQoL was assessed using the EORTC-QLQ-C30 [16] and
the EORTC QLQ-BR23 questionnaires [17] at diagnosis (T0), at
the end of the first hospitalization (T1) and, three (T2) and six
months after the first hospitalization (T3). The QLQ-C30 is a
cancer specific tool composed of 30 items which generate 15
scores: five scores of functional parameters, a financial difficulties
scale, and eight scores for symptoms. The breast cancer module
comprises 23 questions assessing disease symptoms and the side-
effects of treatment. These scores vary from 0 (worst) to 100 (best)
for functional functions and from 0 (best) to 100 (worst) for
symptom parameters.
Patients were also asked to assess their QoL expectations at
baseline using the following question: do you expect that your
QoL:
1) will not change globally,
2) will deteriorate,
3) will improve.
Assessment of the recalibration component of RS using
the then-test method
Recalibration was assessed using the then-test method. This
method requires patients to rate their previous health state from
their current perspective [5,18]. The order in which the QoL
questionnaires, then-test and post-test, were administered was
determined by randomization 1:1 with center stratification to
assess the impact of the order of the questionnaires on RS
estimates. In arm A, patients were asked to complete the
questionnaires at time T (posttest), and then retrospectively
(then-test) to assess baseline QoL at the end of the first
hospitalization. In arm B, the order of the questionnaires was
then-test/post-test. In this study, we did not compare patients
according to randomized arm because previous study showed only
a small impact of the ordre of the randomized arm on QoL scores
[10]. Three then-tests were implemented (figure 1): two to
retrospectively assess baseline QoL (measured at the end of the
first hospitalization and 3 months after the first hospitalization)
and one to retrospectively assess the three-month QoL (measured
at 6 months). In other words, patients were asked to retrospectively
assess their baseline QoL at T1 (then test1) and at T2 (then test 2),
and to retrospectively assess their three-month QoL at T3 (then
test 3).The mean differences between the assessment of the
baseline QoL at the inclusion (pretest) and then test1 were
calculated to assess recalibration at the end of the first
hospitalization. In order to assess recalibration at 3 months, the
mean differences between the assessment of the baseline QoL at
the inclusion and thentest2 were calculated. Lastly, the mean
differences between the three-month QoL and its retrospective
assessment at 6 months (then-test3) were compared in other to
assess recalibration in internal standards at 6 months. A + (or 2)
mean difference between the ‘‘then-test and the pre-test’’
retrospectively reflects a higher (or lower) QoL level at baseline
(or at 3 months) for the functional (or symptoms) dimensions.
Statistical methods
Patients’ characteristics were described and compared accord-
ing to the completion of baseline questionnaire in order to
determine whether missing score at inclusion was dependent on
patients’ clinical or sociodemographic status.
Wilcoxon matched pairs tests were used to assess recalibration.
Time to QoL deterioration. All patients who had a baseline
and at least one follow-up QoL assessment were included in the
TTD analyses.
The time to QoL deterioration (TTD) was defined as the time
from inclusion in the study to the first 5-point [19] decrease in
QoL scores according to baseline score. Patients were censored at
the time of the last QoL completed if they had not deteriorated
before that [14].
To take into account the recalibration component of RS, then-
test assessments were used as reference scores when significant
recalibration effects were observed. Therefore, if significant
recalibration of baseline QoL was observed only at T1 (or at
T2), analyses were done using then-test1 (or then-test2), as the
reference score. In addition, then-test3 was used in TTD analyses
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(instead of three-month QoL), when significant recalibration of the
three-month QoL was observed at T3.
The TTD was estimated using the Kaplan-Meier method. The
TTD was described using medians and the 95% confidence
interval (CI). Statistical significant difference between median
TTD when recalibration component of RS was taken into account
and median TTD when recalibration was not taken into account
was assessed using bootstrap Kaplan-Meier estimate of median
TTD. Nonparametric 95% confidence intervals for the difference
in bootstrap Kaplan-Meier estimate of median TTD were
computed. Differences between medians were considered statisti-
cally significant if their 95% confidence intervals did not include
the value of 0.
Cox regressions were applied to identify factors associated with
TTD for each QoL dimension. All variables with an univariate
Cox p value #0.20 were eligible for multivariate Cox analyses.
Cox multivariate analyses were stratified on the center of
inclusion. The statistical significance level was set at p = 0.05 for
Figure 1. Quality of life data collection procedure.
doi:10.1371/journal.pone.0096848.g001
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Cox models analyses and reduced to p= 0.01 for the analysis
performed with the then-test method in order to prevent false
positive results due to the number of multiple comparisons
performed with this method.
Analyses were performed using STATA Statistics 11/Data
Analysis Software (StataCorp LP, College Station, Texas, USA)
Results
Patients
Between February 2006 and February 2008, 381 patients were
included. Patients’ characteristics have been widely described
elsewhere [10]. Briefly, the mean age was 58 years (SD=11.1),
124 (33%) patients underwent mastectomy, 131(34%) had sentinel
lymph node biopsy (SLNB) and 155 (40%) received adjuvant
chemotherapy (Table 1).
QoL completion
At baseline, 359 (94.2%) patients completed the questionnaire
with at least one available QoL dimension and 357 (93.7%) had a
baseline and at least one follow-up QoL assessment. The clinical
and pathological characteristics of these two populations were
similar and are presented in Table 1. Only the center of inclusion
was statistically different according to missing score.
Response shift
Retrospective assessments of baseline QoL
The occurrence of recalibration effects differed according to the
time of the retrospective assessment (T1 or T2) for 7 dimensions.
For fatigue, appetite loss and the side effects of systemic therapy,
with mean differences (MD) in QoL scores of 21.8(p = 0.0006), 2
2.9(p = 0.0081) and 21.96(p = 0.0001), respectively (Table 2),
symptoms were significantly higher at inclusion than the
retrospective assessment at T1 (then-test1). These differences were
no longer statistically significant with the retrospective assessment
of the baseline QoL at T2 (then-test 2).
Moreover, the MD in global health (GHS), role-functioning and
social-functioning scores as well as body-image were not statisti-
cally significant with then-test1, but became significant with then-
test2. Indeed, QoL scores for GHS, role-functioning, social-
functioning and body-image were significantly higher at inclusion
than the retrospective assessment at T2: MD=23.7(p = 0.0014),
MD=26.3(p,0.0001), MD=23.86(p = 0.0012) and MD=2
6.47(p = 0.0001), respectively (Table 2).
For emotional-functioning, cognitive-functioning, future per-
spectives, diarrhea and insomnia symptoms, the recalibration
effects at T1 and T2 were similar (Table 2). QoL scores were
higher for the retrospective assessments as compared to the
baseline QoL level. MD between then-test2 and pretest scores
were MD=6.89(p,0.0001), MD=3.09(p= 0.0012) and
MD=7.6(p,0.0001) for emotional-functioning, cognitive-func-
tioning and future perspectives, respectively. Insomnia: MD=2
7.25(p = 0.0001) and diarrhea: MD=22.9(p = 0.0019) symptoms
were significantly higher at inclusion the retrospective assessment
(Table 2).
Retrospective assessment of the three months QoL (then-
test3). The retrospective assessment of 3-month QoL scores at
T3 (then-test3), showed that MD between then-test 3 and 3-month
scores were statistically different for most QoL dimensions
(Table 2). For example, QoL scores were higher at the
retrospective assessments (T3) than at 3 months for physical-
functioning (MD=4.3) and role-functioning (MD=6.95). Fur-
thermore, fatigue (MD=29.48), pain (MD=25.07), dyspnea
(MD=23.25) and insomnia (MD=23.96) symptoms were
significantly higher at 3 months than when evaluated retrospec-
tively at T3.
Time to QoL deterioration
Medians TTD for the studied population are shown in table 3.
Results showed that median TTD were significantly shorter when
recalibration was not taken into account than when recalibration
was taken into account for global health, role-functioning, social-
functioning, body-image and side effects of systemic therapy
(figure 2 a to f). For example for GHS, the median TTD increased
from 3.1[2.9–3.3] when recalibration was not taken into account
to 3.6[3.2–6.3] when it was (figure 2a). For role-functioning
(figure 2b), the median TTD increased from 3.2[3.1–3.3] to
4.7[3.3–6.2] when recalibration was taken into account. For social
functioning score (figure 2d), median TTD increased from 3.6
months to 6.3 months when recalibration was taken into account.
For body image score (figure 2e), median TTD increased from 3.3
months to 6.2 months (table 3).
However, for emotional-functioning dimension (figure 2c)
median TTD was significantly longer when recalibration was
not taken into account. Bootstrap Kaplan-Meier estimate of
difference in median TTD was 23.13[23.8–20.5]. For the other
dimensions no statistically significant difference was found
between median TTD.
Univariate analyses of TTD
Results of the univariate Cox analyses of TTD are reported in
table S1 in File S1 for QLQ-C-30 score and table S2 in File S1 for
QLQ-BR23 scores. An MCID of 5 points was used for these
analyses. For example, for the body-image score, when recalibra-
tion was not taken into account, there was no beneficial effect on
TTD of either SLNB or not undergoing radiotherapy. When
recalibration was taken into account, women treated with SLNB
had a significantly longer TTD than those treated with axillary
lymph node dissection (ALND): HR=0.65[0.45–0.93]. Concern-
ing radiotherapy, patients who did not receive treatment by
radiotherapy had a significantly longer TTD than those who
underwent radiotherapy.
Cox multivariate analyses of TTD
Multivariate Cox models analyses were done for all dimensions
of the QLQ-C30 and BR-23 questionnaire. However, for
parsimony of the presentation, only dimensions (of QLQ-C30 or
BR23) where times to deterioration estimations were significantly
influenced by factors are shown in table 4. For body-image, when
RS was not taken into account, cox multivariate analyses showed
that the modality of surgery was significantly associated with TTD.
Patients who underwent mastectomy had a shorter TTD for body-
image as compared to patient having conservative surgery: HR
1.8[1.3–2.5].
When recalibration was taken into account for body-image, the
association between TTD and the modality of surgery became
non-statistically significant while radiotherapy became significantly
associated with TTD. Patients who did not receive radiotherapy
had a significantly longer TTD than did those who received
radiotherapy: HR 0.60 [0.38–0.94].
Cox multivariate analyses showed that, expectation about QoL
level at baseline was significantly associated with TTD. As
example, when the recalibration component of RS was taken into
account, QoL expectancy at baseline was significantly associated
with TTD in GHS, physical-functioning, cognitive-functioning,
social-functioning, and breast symptoms scales. Patients who
expected a deterioration in their QoL at baseline had a
Quality of Life Analysis and Response-Shift
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Table 1. Characteristics of patients according to the completion of quality of life questionnaire at baseline.
Patients with at least one baseline
score (359)
Patients without baseline
score (22) Fisher exact test
N (%) N (%)
Lymph node dissection(LND)
Axillary LND 127 35.4 11 50 0.363
Sentinel lymph node biopsy 124 34.5 7 31.8
ALND+SLNB 32 8.9 0 0
No LND 72 20.1 3 13.6
unknown 4 1.1 4 4.6
Surgery type 1.000
mastectmoy 117 32.6 7 31.8
no mastectomy 227 63.2 14 63.6
unknown 15 4.2 1 4.6
Chemotherapy 0.500
yes 148 41.2 7 31.8
no 204 56.8 14 63.6
unknown 7 2 1 4.6
Radiotherapy 0.814
yes 239 66.6 15 68.2
no 113 31.5 6 27.3
unknown 7 2 1 4.6
Hormone therapy 0.509
yes 162 45.1 8 36.4
no 190 52.9 13 59.1
unknown 7 2 1 4.6
Care center 0.030
Dijon 250 69.6 21 95.5
Nancy 74 20.6 0 0
Reims 17 4.7 1 4.6
Strasbourg 18 5 0 0
Comorbidity 0.162
yes 229 63.8 10 45.5
no 128 35.7 11 50
unknown 2 0.6 1 4.6
Stage (AJCC) 0.555
0 76 21.2 2 9.1
1 126 35.1 9 40.9
2 111 30.9 7 31.8
3_4 15 4.2 0 0
unknown 31 8.6 4 18.2
Marital status 0.309
married 262 73 19 86.4
Not married 87 24.2 3 13.6
unknown 10 2.8 0 0
Live alone 0.391
yes 59 16.4 2 9.1
no 260 72.4 19 86.4
unknown 40 11.1 1 4.6
Education Degree 0.204
low level 156 43.5 11 50
high level 150 41.8 5 22.7
Quality of Life Analysis and Response-Shift
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significantly shorter TTD than patients who expected an
improvement in their QoL at baseline HR: 1.60[1.05–2.45],
HR: 1.95[1.33–2.86], HR: 1.64[1.07–2.52] and HR: 1.75[1.11–
2.75] for GHS, physical, cognitive and social scores, respectively.
Discussion
In this study, we examined the impact of the recalibration
component of response shift on TTD estimations of QoL scores in
breast cancer patients. Our results underlined that BC patients’
internal standards for assessing their QoL could change during the
course of treatment and disease.
The recalibration of BC patients’ internal standards had a
significant effect on Time to QoL score deterioration for six of the
23 dimensions. Indeed, the median TTD of the studied-population
was underestimated for global health, role-functioning, social-
functioning, body-image and side effects of systemic therapy when
recalibration was not used as reference score to qualify QoL score
deterioration. Regarding the emotional-functioning scale, the
median TTD was overestimated when recalibration was not taken
into account.
Our results showed that, as compared to ALND SLNB modality
was independently associated with longer TTD for arm symptoms,
nausea and vomiting symptoms as well as systemic therapy side
effects [14,20–23]. Interestingly, for breast symptoms, our results
showed that SLNB followed by complementary ALND resulted in
a significantly shorter TTD than for ALND alone [14]. According
the surgical modality, TTD was significantly associated with
diarrhea symptoms when recalibration was take into account. In
contrast, for body-image, we found a significant association
between the type of surgery and TTD only when the recalibration
effect was not take into account. To our knowledge, no study
reporting the association between the type of surgery and QoL has
considered the effect of the recalibration component of RS [24–
27]. In addition, we suggest that radiotherapy could be
independently associated with a shorter time to body-image
deterioration, when RS into account. These results underline the
requirement to assess impact of RS through sensibility analyses.
Moreover, patients who expected deterioration or no change in
their QoL level reported a significantly shorter TTD than patients
who expected an improvement. Previous studies have also
suggested that the high expectation of patients regarding health
and QoL level, could predict better outcome [2,28–31,]. Although,
heterogeneity between studies clinical outcome, investigators have
consistently and in a majority shown strong, statistically and
clinically significant associations between patients’ expectations
and clinical recovery. However, the interpretation of this
association remains unclear. Incorporating questions about patient
expectations related to health and QoL in future trials should be
promote to clarify the role for clinical outcomes.
One of the limits of our study is that we focused on the
recalibration component of response-shift only using then test
method.
Furthermore due to the retrospective assessment, a major
limitation of the then-test method is its susceptibility to recall bias.
Thereby, respondents are supposed to be able to remember their
previous health and QoL level at the baseline assessment [18,32].
The risk when using this approach could be that patients will miss
to accurately recall their health and QoL level before the
intervention (recall bias). Additionally, recent evidence has
emerged amongst patients undertaking self-management interven-
tions for chronic diseases that the then-test approach may contain
psychometric flaws resulting from implicit theory of change, social
desirability, halo effects and recall bias [33]. Including a
comparison group when designing studies could help to achieve
optimal use of the then-test approach. However, RS has been
defined as a treatment-dependent phenomenon, pre-test, post-test
and then-test scores of control subjects would only reflect effects
due to history, maturation or testing. Thus, recalibration RS is
only indicated if the difference between the then-test and pre-test
scores are significantly larger in the experimental than in the
control group [18].
Response shift has been explored over time in HRQoL through
a variety of designs and statistical methods. Each of these methods
is specific, with its own advantages, limitations and challenges.
However, assessing response shift is of paramount importance in
longitudinal HRQoL research.
In conclusion, our study showed that BC patients’ internal
standards change during QoL follow-up. Since patients could
accommodate to the treatment toxicities or disease progression
over time, this could result in the attenuation or the inflation of
treatment effect estimation. Therefore, cancer clinical trials must
investigate the RS effect more deeply. We encourage to plan
longitudinal QoL analyses taking it into account such effect to
improve interpretation of the results. Our study also showed that
baseline QoL expectations were associated with QoL deterioration
in several dimensions. For this reason, health care providers should
give adequate counselling and psychological support to the
patients at the time of the diagnosis to prevent the early QoL
level deterioration.
Table 1. Cont.
Patients with at least one baseline
score (359)
Patients without baseline
score (22) Fisher exact test
N (%) N (%)
unknown 53 14.8 6 27.3
Job 0.491
working 173 48.19 8 36.36
not working 172 47.91 12 54.55
unknown 14 3.9 2 9.1
Mean SD Mean SD p Mann&Whitney
Age 57.8 11.1 61.3 9.9
doi:10.1371/journal.pone.0096848.t001
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Figure 2. Time to deterioration in QoL score in the studied population with response shift (RS) taken into account or not. a) for the
general health score of the QLQ-C30. b) for the role functioning score of the QLQ-C30. c) for emotional functioning. d)for social functioning. e) for
body image. f) for systematic therapy side effects.
doi:10.1371/journal.pone.0096848.g002
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